Delayed methotrexate clearance in a patient with sickle cell anemia and osteosarcoma

Journal of Pediatric Hematology/Oncology

Volumn 21, Issue 2, 1999, Pages 165-169

  Mantadakis, Elpis ^a,b   Rogers, Zora R ^a,b   Smith, Angela K ^a,b   Quigley, Raymond ^a   Ratliff, Arleen F ^a,b   Kamen, Barton A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

Author keywords

Carboxypeptidase G2; Hepatotoxicity; Leucovorin; Methotrexate rescue; Neurologic toxicity; Osteosarcoma; Renal failure; Sickle cell anemia; Thymidine

Indexed keywords

CARBOXYPEPTIDASE G2; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; MAGNESIUM; METHOTREXATE; RAZOXANE; THYMIDINE;

ADOLESCENT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TONIC CLONIC SEIZURE;

ADOLESCENT; AMPUTATION; ANEMIA, SICKLE CELL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DOXORUBICIN; EPILEPSY, TONIC-CLONIC; FEMALE; GAMMA-GLUTAMYL HYDROLASE; HEPATITIS, TOXIC; HUMANS; KIDNEY DISEASES; LEUCOVORIN; METABOLIC CLEARANCE RATE; METHOTREXATE; OSTEOSARCOMA; PAIN; THYMIDINE; TIBIA;

EID: 0033503850     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199903000-00016     Document Type: Article

References (42)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
2. Dawkins FW, Kim KS, Squires RS, et al. Cancer incidence rate and mortality in sickle cell disease patients at Howard University Hospital: 1986-1995. Am J Hematol 1997;55:188-92.
3. Labi M, Haponik EF, Welsch RA, et al. Alveolar cell carcinoma complicating sickle cell disease: a chance occurrence? Am J Hematol 1989;32:222-5.
4. Sarma PS, Chawda BK, Das SR. Chronic myelocytic leukemia in a patient with sickle cell anemia. J Assoc Physicians India 1986;34:821-2.
5. Phillips G Jr, Hartman J, Kinney TR, et al. Chronic granulocytic leukemia in a patient with sickle cell anemia. Am J Med 1988;85:567-9.
6. Frierson HF Jr, Fechner RE, Stallings RG, et al. Malignant fibrous histiocytoma in bone infarct: association with sickle cell trait and alcohol abuse. Cancer 1987;59:496-500.
7. Mirra JM, Gold RH, Marafiote R. Malignant (fibrous) histiocytoma in association with a bone infarct in sickle-cell disease: coincidence or cause-and-effect? Cancer 1977;39:186-94.
8. Mirra JM, Bullough PG, Marcove RC, et al. Malignant fibrous histiocytoma and osteosarcoma in association with bone infarcts: report of four cases, two in caisson workers. J Bone Joint Surg Am 1974;56:932-40.
9. Resnik CS, Aisner SC, Young JW, Levine A. Case report 767: osteosarcoma arising in bone infarction. Skeletal Radiol 1993;22:58-61.
10. Stricker RB, Linker CA, Crowley TJ, et al. Hematologic malignancy in sickle cell disease: report of four cases and review of the literature. Am J Hematol 1986;21:223-30.
11. Morabito F, Callea V, Brugiatelli M, et al. Non-Hodgkin's lymphoma associated with sickle cell disease: a case report. Tumori 1987;73:523-4.
12. Bigner SH, Friedman HS, Kinney TR, et al. 9p-in a girl with acute lymphocytic leukemia and sickle cell disease. Cancer Genet Cytogen 1986;21:267-9.
13. Sarma PS, Viswanathan KA, Mukherjee MM. Multiple myeloma in a patient with sickle cell anemia. J Assoc Physicians India 1986;34:877-8.
14. Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma: the seventh sickle cell nephropathy. Am J Surg Pathol 1995;19:1-11.
15. Cassano WF, Graham-Pole J, Dickson N. Etoposide, cyclophosphamide, cisplatin, and doxorubicin as neoadjuvant chemotherapy for osteosarcoma. Cancer 1991;68:1899-902.
16. Blum RH. Clinical status and optimal use of the cardioprotectant dexrazoxane. Oncology 1997;11:1669-77.
17. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
18. Grem JL, King SA, Wittes RE, et al. The role of methotrexate in osteosarcoma. J Natl Cancer Inst 1988;80:626-55.
19. Von Hoff DD, Penta JS, Helman LJ, et al. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 1977;61:745-8.
20. Stoller RG, Jacobs SA, Drake JC, et al. Pharmacokinetics of high-dose methotrexate. Cancer Chemother Rep 1975;6:19-24.
21. Jacobs SA, Stoller RG, Chabner BA, et al. 7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 1976;57:534-8.
22. Sasaki K, Hosoya R, Wang YM, et al. Formation and disposition of 7-hydroxymethotrexate in rabbits. Biochem Pharmacol 1983;32:503-7.
23. Kremer JM, Hamilton RA. The effects of nonsteroidal anti-inflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995;22:2072-7.
24. Bertin P, Carpentier N, Vergne P, et al. Methotrexate and nonsteroidal anti-inflammatory agent combination in rheumatoid arthritis. Therapie 1997;52:133-7.
25. Condit PT, Chanes RE, Joel W. Renal toxicity of methotrexate. Cancer 1969;23:126-31.
26. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987;5:2017-31.
27. Buckalew VM Jr, Someran A. Renal manifestations of sickle cell disease. Arch Intern Med 1974;133:660-9.
28. de Jong PE, Statius van Eps LW. Sickle cell nephropathy: new insights into its pathophysiology. Kidney Int 1985;27:711-7.
29. Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med 1990;150:501-4.
30. Hande KR, Balow JE, Drake JC, et al. Methotrexate and hemodialysis. Ann Intern Med 1977;87:495-6.
31. Ahmad S, Shen FH, Bleyer WA. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med 1978;138:1146-7.
32. Gibson TP, Reich SD, Krumlovsky FA, et al. Hemoperfusion for methotrexate removal. Clin Pharmacol Ther 1978;23:351-5.
33. Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997;15:2125-34.
34. Widemann BC, Hetherington ML, Murphy RF, et al. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 1995;76:521-6.
35. DeAngelis LM, Tong WP, Lin S, et al. Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol 1996;14:2145-9.
36. Zoubek A, Zaunschirm HA, Lion T, et al. Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol 1995;12:471-7.
37. Chaimovitz C, Abinader E, Benderly A, et al. Hypocalcemic hypotension. JAMA 1972;222:86-7.
38. Yim YS, Mahoney DH Jr, Oshman DG. Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991;67:2058-61.
39. Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - a Pediatric Oncology Group study. J Clin Oncol 1998;16:1712-22.
40. Quinn CT, Griener JC, Bottiglieri T, et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997;15:2800-6.
41. Ohmoto Y, Kajiwara K, Kato S, et al. Atypical MRI findings in treatment-related leukoencephalopathy: case report. Neuroradiology 1996;38:128-33.
42. Kamen BA, Takach PL, Vatev R, et al. A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 1976;70:54-63.